Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors

[1]  Michael L. Gatza,et al.  Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.

[2]  Le Xu,et al.  High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma , 2015, Scientific Reports.

[3]  Tal Galili,et al.  dendextend: an R package for visualizing, adjusting and comparing trees of hierarchical clustering , 2015, Bioinform..

[4]  M. Gleave,et al.  Targeting ASCT2‐mediated glutamine uptake blocks prostate cancer growth and tumour development , 2015, The Journal of pathology.

[5]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[6]  G. Qing,et al.  ATF4 and N‐Myc coordinate glutamine metabolism in MYCN‐amplified neuroblastoma cells through ASCT2 activation , 2015, The Journal of pathology.

[7]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[8]  J. Rasko,et al.  Targeting glutamine transport to suppress melanoma cell growth , 2014, International journal of cancer.

[9]  Hong Ma,et al.  Upregulated SLC1A5 promotes cell growth and survival in colorectal cancer. , 2014, International journal of clinical and experimental pathology.

[10]  Jae-Hoon Chang,et al.  Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. , 2014, Immunity.

[11]  Jingchun Zhu,et al.  Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report , 2014, Molecular & Cellular Proteomics.

[12]  Y. Tomizawa,et al.  ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer , 2014, British Journal of Cancer.

[13]  J. Tamburini,et al.  Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. , 2013, Blood.

[14]  Jean Qiu,et al.  The metabolic demands of cancer cells are coupled to their size and protein synthesis rates , 2013, Cancer & Metabolism.

[15]  Matthew G. Vander Heiden,et al.  Exploiting tumor metabolism: challenges for clinical translation , 2013 .

[16]  K. Hedfalk,et al.  Large scale production of the active human ASCT2 (SLC1A5) transporter in Pichia pastoris--functional and kinetic asymmetry revealed in proteoliposomes. , 2013, Biochimica et biophysica acta.

[17]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Simen Myhre,et al.  Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins , 2013, Molecular oncology.

[19]  A. Paiardini,et al.  Glycine consumption and mitochondrial serine hydroxymethyltransferase in cancer cells: the heme connection. , 2013, Medical hypotheses.

[20]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[21]  M. Adeva,et al.  Ammonium metabolism in humans. , 2012, Metabolism: clinical and experimental.

[22]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[23]  C. Schmidt,et al.  Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs , 2012, Oncogenesis.

[24]  V. Mootha,et al.  Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation , 2012, Science.

[25]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[27]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[28]  R. Deberardinis,et al.  Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? , 2012, Cell.

[29]  T. Fan,et al.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. , 2012, Cell metabolism.

[30]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[31]  K. Coombes,et al.  Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer , 2011, Clinical Proteomics.

[32]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  E. Petricoin,et al.  Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. , 2011, The American journal of pathology.

[34]  M. V. Vander Heiden.  Targeting cancer metabolism: a therapeutic window opens. , 2011, Nature reviews. Drug discovery.

[35]  Heiko A. Mannsperger,et al.  RPPanalyzer: Analysis of reverse-phase protein array data , 2010, Bioinform..

[36]  C. Thompson,et al.  Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.

[37]  T. Bathen,et al.  Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy , 2010, NMR in biomedicine.

[38]  Peter Dalgaard,et al.  R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .

[39]  J. Reis-Filho,et al.  Histological and molecular types of breast cancer: is there a unifying taxonomy? , 2009, Nature Reviews Clinical Oncology.

[40]  Yibing Yan,et al.  Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays , 2008, Molecular Cancer Therapeutics.

[41]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Stefan Wiemann,et al.  Infrared‐based protein detection arrays for quantitative proteomics , 2007, Proteomics.

[43]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[44]  B. Fuchs,et al.  Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? , 2005, Seminars in cancer biology.

[45]  M. Peppelenbosch,et al.  Single cell proteomics for personalised medicine. , 2004, Trends in molecular medicine.

[46]  D. Lavillette,et al.  N-Linked Glycosylation and Sequence Changes in a Critical Negative Control Region of the ASCT1 and ASCT2 Neutral Amino Acid Transporters Determine Their Retroviral Receptor Functions , 2003, Journal of Virology.

[47]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[48]  V. Young,et al.  Glutamine: the emperor or his clothes? , 2001, The Journal of nutrition.

[49]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[50]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[51]  S. Gygi,et al.  Correlation between Protein and mRNA Abundance in Yeast , 1999, Molecular and Cellular Biology.

[52]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[53]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[54]  D. Harrington.  A class of rank test procedures for censored survival data , 1982 .

[55]  O. Warburg.  On the origin of cancer cells. , 1956, Science.